Clinical trial · Interventional
Concurent Chemoradiotherapy in Head and Neck Cancers
Phase III Study Comparing Concurrent Chemoradiotherapy With Weekly Docitaxel Plus Cisplatin Versus the Standard Concurrent Radiotherapy With Cisplatin in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
NCT04780750CI-TRIAL-00050425unknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To compare the efficacy and toxicities of the combination between weekly docitaxel and cisplatin (every3 week) concurrent with radiation versus the standard concurrent chemoradiotherapy with high dose cisplatin (100mg\\m2) for locally advanced HNSCC
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Squamous Cell Carcinoma of Head and Neck | Head and Neck Squamous Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Docetaxel | Drug | Docetaxel | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Arm A concurrent chemoradiotherapy with weekly docitaxel and cisplatin every 3 weeks
- description
- Arm A (tested regimen): concurrent chemoradiotherapy with weekly docitaxel (20 mg\\m2) and cisplatin (80mg\\m2 every 3 weeks)
- interventionNames
- Drug: Docetaxel
- type
- ACTIVE_COMPARATOR
- label
- Arm B :concurrent chemoradiotherapy with cisplatin every 3 weeks
- description
- Arm B (standard regimen):concurrent chemoradiotherapy with cisplatin (100mg\\m2 every 3 weeks)
- interventionNames
- Drug: Docetaxel
Primary outcomes (1)
- measure
- locoregional recurrence free survival in months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * pathologically confirmed squmous cell carcinoma performance status 0-1 adequte renal and hepatic function Exclusion Criteria: * poor performance status * impaired renal or hepatic function =Squamous cell carcinoma of salivary gland,parotid and paranasal carcinomas were --0excluded from the study * patients with ≥ grade 2 pre-existing peripheral neuropathy, history of allergic reactions to the chemotherapeutic agents, and uncontrolled intercurrent diseases as well as HIV positive patients.
References
Publications (0)
Data not yet available
No reference posted for this study.